Company / R&D Expense
INSMED Inc R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$771.1M
FY2025
5-year range
$272.7M / $771.1M
FY2021-FY2025
Trend
+28.9%
vs FY2024
Sector context
#26 of 210
Health Care
What the data says
INSMED Inc's r&d expense of $771M is higher than 88% of companies in the Health Care sector (FY2025). R&D Expense has increased for 6 consecutive years, from $132M in FY2019 to $771M in FY2025.
Based on SEC 10-K filings.
$771M in FY2025 with a 5-year CAGR of +33.6%. Top quartile in the Health Care sector.
Improved from $571M to $771M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +24.7%
- 5-Year CAGR
- +33.6%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 210This company $771.1M Sector average $644.1M
▼
+19.7% above sector average
Key checks
Key Insights
- INSMED Inc's r&d expense has grown for 6 consecutive years.
- 5-year CAGR of +33.6%, indicating consistent growth.
- In FY2025, r&d expense increased 28.9% year-over-year.
- Ranks #26 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.93 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $771.1M | +28.9% |
| FY2024 | $598.4M | +4.8% |
| FY2023 | $571.0M | +43.6% |
| FY2022 | $397.5M | +45.7% |
| FY2021 | $272.7M | +50.6% |
| FY2020 | $181.2M | +37.5% |
| FY2019 | $131.7M | -9.3% |
| FY2018 | $145.3M | +32.4% |
| FY2017 | $109.7M | -10.6% |
| FY2016 | $122.7M | +65.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026